slot ph club

Does she realise the ramifications a closing down of the greyhound industry would cause? There are approximately eight or nine thousand greyhounds in NSW; racing, puppies and young ones ready to race as well as adopted. What do you think would happen to these beautiful greyhounds if this should happen? In my opinion there is only one answer and it’s not a very pleasant one. We all know accidents happen every week in all manner of sports.

Primo Brands ( NYSE:PRMB – Get Free Report ) is one of 18 public companies in the “Bottled & canned soft drinks” industry, but how does it contrast to its competitors? We will compare Primo Brands to related companies based on the strength of its valuation, dividends, profitability, analyst recommendations, earnings, risk and institutional ownership. Risk and Volatility Primo Brands has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Primo Brands’ competitors have a beta of 0.90, indicating that their average stock price is 10% less volatile than the S&P 500. Earnings & Valuation This table compares Primo Brands and its competitors revenue, earnings per share and valuation. Insider & Institutional Ownership 87.7% of Primo Brands shares are owned by institutional investors. Comparatively, 48.3% of shares of all “Bottled & canned soft drinks” companies are owned by institutional investors. 2.5% of Primo Brands shares are owned by company insiders. Comparatively, 14.5% of shares of all “Bottled & canned soft drinks” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Dividends Primo Brands pays an annual dividend of $0.36 per share and has a dividend yield of 1.2%. Primo Brands pays out 22.4% of its earnings in the form of a dividend. As a group, “Bottled & canned soft drinks” companies pay a dividend yield of 1.0% and pay out 19.1% of their earnings in the form of a dividend. Analyst Recommendations This is a summary of current ratings for Primo Brands and its competitors, as reported by MarketBeat.com. Primo Brands presently has a consensus target price of $33.00, indicating a potential upside of 5.94%. As a group, “Bottled & canned soft drinks” companies have a potential upside of 26.02%. Given Primo Brands’ competitors higher possible upside, analysts clearly believe Primo Brands has less favorable growth aspects than its competitors. Profitability This table compares Primo Brands and its competitors’ net margins, return on equity and return on assets. Summary Primo Brands competitors beat Primo Brands on 8 of the 15 factors compared. About Primo Brands ( Get Free Report ) Primo Water Corporation is a leading pure-play water solutions provider in North America and Europe. Primo operates largely under a recurring razor/razorblade revenue model. The razor in Primo’s revenue model is its industry leading line-up of sleek and innovative water dispensers, which are sold through major retailers and online at various price points or leased to customers. The dispensers help increase household penetration, which drives recurring purchases of Primo’s razorblade offering. Primo’s razorblade offering is comprised of Water Direct, Water Exchange, and Water Refill. Primo’s water solutions expand consumer access to purified, spring and mineral water to promote a healthier, more sustainable lifestyle while simultaneously reducing plastic waste and pollution. Primo is committed to its water stewardship standards and is proud to partner with the International Bottled Water Association in North America as well as with Watercoolers Europe. Receive News & Ratings for Primo Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Primo Brands and related companies with MarketBeat.com's FREE daily email newsletter .One of the UK’s oldest comic book shops announces closure after ‘epic’ 43 years ahead of huge clearance saleJimmy Carter Passes Away With One Final Parting Gift for Trump

By MICHELLE L. PRICE WEST PALM BEACH, Fla. (AP) — An online spat between factions of Donald Trump’s supporters over immigration and the tech industry has thrown internal divisions in his political movement into public display, previewing the fissures and contradictory views his coalition could bring to the White House. The rift laid bare the tensions between the newest flank of Trump’s movement — wealthy members of the tech world including billionaire Elon Musk and fellow entrepreneur Vivek Ramaswamy and their call for more highly skilled workers in their industry — and people in Trump’s Make America Great Again base who championed his hardline immigration policies. The debate touched off this week when Laura Loomer , a right-wing provocateur with a history of racist and conspiratorial comments, criticized Trump’s selection of Sriram Krishnan as an adviser on artificial intelligence policy in his coming administration. Krishnan favors the ability to bring more skilled immigrants into the U.S. Loomer declared the stance to be “not America First policy” and said the tech executives who have aligned themselves with Trump were doing so to enrich themselves. Much of the debate played out on the social media network X, which Musk owns. Loomer’s comments sparked a back-and-forth with venture capitalist and former PayPal executive David Sacks , whom Trump has tapped to be the “White House A.I. & Crypto Czar.” Musk and Ramaswamy, whom Trump has tasked with finding ways to cut the federal government , weighed in, defending the tech industry’s need to bring in foreign workers. It bloomed into a larger debate with more figures from the hard-right weighing in about the need to hire U.S. workers, whether values in American culture can produce the best engineers, free speech on the internet, the newfound influence tech figures have in Trump’s world and what his political movement stands for. Trump has not yet weighed in on the rift. His presidential transition team did not respond to questions about positions on visas for highly skilled workers or the debate between his supporters online. Instead, his team instead sent a link to a post on X by longtime adviser and immigration hard-liner Stephen Miller that was a transcript of a speech Trump gave in 2020 at Mount Rushmore in which he praised figures and moments from American history. Musk, the world’s richest man who has grown remarkably close to the president-elect , was a central figure in the debate, not only for his stature in Trump’s movement but his stance on the tech industry’s hiring of foreign workers. Technology companies say H-1B visas for skilled workers, used by software engineers and others in the tech industry, are critical for hard-to-fill positions. But critics have said they undercut U.S. citizens who could take those jobs. Some on the right have called for the program to be eliminated, not expanded. Born in South Africa, Musk was once on an a H-1B visa himself and defended the industry’s need to bring in foreign workers. “There is a permanent shortage of excellent engineering talent,” he said in a post. “It is the fundamental limiting factor in Silicon Valley.” Trump’s own positions over the years have reflected the divide in his movement. Related Articles National Politics | Trump threat to immigrant health care tempered by economic hopes National Politics | In states that ban abortion, social safety net programs often fail families National Politics | Trump vows to pursue executions after Biden commutes most of federal death row National Politics | Elon Musk’s preschool is the next step in his anti-woke education dreams National Politics | Trump’s picks for top health jobs not just team of rivals but ‘team of opponents’ His tough immigration policies, including his pledge for a mass deportation, were central to his winning presidential campaign. He has focused on immigrants who come into the U.S. illegally but he has also sought curbs on legal immigration , including family-based visas. As a presidential candidate in 2016, Trump called the H-1B visa program “very bad” and “unfair” for U.S. workers. After he became president, Trump in 2017 issued a “Buy American and Hire American” executive order , which directed Cabinet members to suggest changes to ensure H-1B visas were awarded to the highest-paid or most-skilled applicants to protect American workers. Trump’s businesses, however, have hired foreign workers, including waiters and cooks at his Mar-a-Lago club , and his social media company behind his Truth Social app has used the the H-1B program for highly skilled workers. During his 2024 campaign for president, as he made immigration his signature issue, Trump said immigrants in the country illegally are “poisoning the blood of our country” and promised to carry out the largest deportation operation in U.S. history. But in a sharp departure from his usual alarmist message around immigration generally, Trump told a podcast this year that he wants to give automatic green cards to foreign students who graduate from U.S. colleges. “I think you should get automatically, as part of your diploma, a green card to be able to stay in this country,” he told the “All-In” podcast with people from the venture capital and technology world. Those comments came on the cusp of Trump’s budding alliance with tech industry figures, but he did not make the idea a regular part of his campaign message or detail any plans to pursue such changes.

Cam Carter put LSU ahead for good with a jumper 1:08 into the third overtime and the Tigers came away with a wild 109-102 win over UCF on Sunday in the third-place game of the Greenbrier Tip-Off in White Sulphur Springs, W.Va. Carter's make sparked a 5-0 spurt for LSU (5-1), which mounted a ferocious second-half rally that began after Darius Johnson drilled a 3-pointer to put the Knights up 52-34 with 12:57 to play in regulation. UCF (4-2) got back within two in the third overtime, but it never found a way to draw even. Vyctorius Miller and Jordan Sears sealed the victory, combining for three buckets down low that gave the Tigers a 106-99 cushion with 17 seconds remaining. Carter was the late-game hero for LSU, scoring the final four points of regulation to forge a 70-70 tie. He also knocked down a go-ahead 3-pointer with 3:19 left in the first extra session to give the Tigers a 76-75 advantage. Sears gave LSU a four-point edge with a triple of his own with 2:10 to go, but the Tigers failed to stay in front, and UCF's Keyshawn Hall kept the game going by sinking two free throws with six seconds remaining to make it 82-82. Neither team led by more than three in the second overtime, with Hall again coming to the Knights' rescue. He made two layups in the final 52 seconds of the frame to knot things at 93 and send the teams to a third OT. Few could have predicted 15 minutes of extra basketball after UCF put together a 25-3 first-half run that lifted it to a 38-18 advantage with 2:12 left until the break. LSU responded with seven unanswered points, but the Knights still led comfortably, 40-25, at intermission. Sears finished with a game-high-tying 25 points to go along with nine boards, while Jalen Reed recorded a 21-point, 13-rebound double-double for the Tigers. Carter netted 20 points, Miller had 16 and Dji Bailey chipped in 14. Johnson collected 25 points, six rebounds, eight assists and five steals for UCF. Hall totaled 21 points and 10 boards, and Jordan Ivy-Curry supplied 20 points. LSU outshot UCF 43.2 percent to 40.7 percent and had narrow advantages from behind the arc (12 made shots to 10) and the free-throw line (21-18). --Field Level MediaMark Carney’s Brookfield pay remains mysterious, to the detriment of all Canadians2 Oregon men die from exposure in forest after Sasquatch searchWorld Reacts To Life, Passing Of Former President Jimmy Carter

WEST POINT, N.Y. (AP) — Jalen Rucker's 27 points helped Army defeat UTSA 78-75 on Sunday night. Rucker added six rebounds for the Black Knights (6-6). Ryan Curry scored 15 points while shooting 4 for 9 (3 for 8 from 3-point range) and 4 of 5 from the free-throw line and added five assists. AJ Allenspach shot 4 of 4 from the field and 4 for 5 from the foul line to finish with 12 points, while adding eight rebounds. The Roadrunners (6-6) were led by Amir "Primo" Spears, who recorded 22 points and nine rebounds. Tai'Reon Joseph added 16 points and two steals for UTSA. Raekwon Horton finished with 15 points, seven rebounds and three steals. Army went into halftime ahead of UTSA 39-35. Rucker scored 11 points in the half. Rucker scored 16 points down the stretch in the second half to help lead Army to a three-point victory. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .Jhon Duran slapped with BAN after FA reject Aston Villa’s appeal to overturn red card against Newcastle

What do many kids like most about the coming of a new year? The fireworks. Investors don't mind seeing some fireworks in their portfolios with a new year starting, either. Three Motley Fool contributors think they have found stocks that could provide a big bang for growth investors . Here's why they believe Novo Nordisk ( NVO -0.32% ) , Summit Therapeutics ( SMMT -5.55% ) , and Viking Therapeutics ( VKTX -3.56% ) could be monster winners for 2025. Novo Nordisk could be due for a big comeback in 2025 David Jagielski (Novo Nordisk): It's been a tough 2024 for drugmaker Novo Nordisk. Entering this week, its shares were down 14% as the company behind the popular diabetes drug Ozempic has been generating good growth, but that hasn't been enough to win over investors. To make things worse, the company recently unveiled results from a trial involving weight loss treatment CagriSema. In a late-stage trial, the drug helped participants lose an average of 22.7% of their weight, versus the 25% that was expected. The stock fell by around 20% on the news in what looked to be a gross overreaction about what may still be the top weight loss drug in the future. The company already has an approved weight loss treatment in Wegovy, which shares the same active ingredient (semaglutide) with Ozempic. CagriSema's trial results were by no means awful, but the market has already responded in a big (negative) way. The sell-off in the stock has pushed it near its 52-week low, and it's now trading at 22 times next year's estimated future earnings (based on analyst estimates). Given its low valuation and the seeming overreaction in the markets to the recent trial results, this is a stock that could generate monster gains next year as a rebound could be in the cards. Novo Nordisk has been investing in additional manufacturing capacity to help meet the surging demand for its weight loss and diabetes treatments, and its results have been great in recent quarters. The business has been growing its operating profit by 21% through the first nine months of this year. And with a lot more growth still ahead for the business, investors should be careful not to overlook Novo Nordisk -- the healthcare stock could have plenty of upside next year. A potential blockbuster on the way Keith Speights (Summit Therapeutics): 2024 has been a fantastic year for Summit Therapeutics, with its stock delivering an explosive 7x gain. I think the new year will bring more good fortune for this up-and-coming drugmaker. Summit expects to announce top-line results in mid-2025 from a phase 3 study evaluating ivonescimab in combination with chemotherapy as a second-line treatment for advanced non-small cell lung cancer (NSCLC). The U.S. Food and Drug Administration (FDA) has already granted Fast Track Designation to the therapy for this indication. This means the approval process could be expedited and guarantees the FDA will work closely with Summit on advancing ivonescimab. To be sure, there's a degree of risk associated with any clinical trial. However, Summit's chances of success with this late-stage study appear to be great. Why? The company's partner, Chinese pharmaceutical company Akeso , reported spectacular results from its phase 3 study of ivonescimab earlier this year as a first-line treatment for NSCLC. Patients receiving the drug experienced significantly increased progression-free survival rates than patients receiving Merck 's Keytruda immunotherapy. It's important to note that Keytruda ranked as the world's top-selling drug last year with sales of $25 billion. With ivonescimab outperforming Keytruda in Akeso's late-stage study, I predict Summit will have a blockbuster drug on its hands in the not-too-distant future. And Summit won't be content with the second-line NSCLC indication. The company is evaluating ivonescimab in combination with chemotherapy in a late-stage study as a first-line NSCLC therapy. It also plans to initiate another phase 3 study of the drug as a monotherapy in the first-line NSCLC setting. Lightning can strike the same place twice Prosper Junior Bakiny (Viking Therapeutics): Can a stock deliver monster returns two years in a row? Under the right conditions, the answer is yes. Consider Viking Therapeutics, a mid-cap biotech that soared this year following excellent phase 2 results for its investigational weight loss medicine, VK2735. The company should make progress on this program next year, when it will probably start a phase 3 study. It is also working on an investigational medicine for metabolic dysfunction-associated steatohepatitis, which should also enter pivotal trials in 2025. Viking has more promising early-stage candidates, and progress from those could be what jolts the stock price. Its oral formulation of VK2735 is a good example. Billion-dollar weight loss medicines like Zepbound and Wegovy are administered via injection. An oral formulation would be a welcome sight for many patients. Although several drugmakers are working on this project , Viking has more upside potential than the large leading pharmaceutical companies, while smaller ones haven't shown the kinds of results it has so far. And the company is still working on promising anti-obesity programs. It recently reported encouraging pre-clinical results from a brand-new clinical compound. Viking is looking to establish itself as a leader in this therapeutic area, which happens to be the hottest and one of the fastest-growing in the industry. It has shown more promise in the field than most other companies, even those with far more resources than it has. So, Viking Therapeutics' shares could once again soar next year and deliver strong performance in the next half-decade.

PHILADELPHIA and NEW YORK , Dec. 27, 2024 /PRNewswire/ -- FS KKR Capital Corp. FSK today announced that it has completed its previously announced offering of an additional $100 million in aggregate principal amount of its 6.125% notes due 2030 (the "Notes"). The Notes will be a further issuance of, and form a single series with, the $600 million aggregate principal amount of 6.125% Notes due 2030 that FSK issued on November 20, 2024 , increasing the outstanding aggregate principal amount of the series to $700 million . BofA Securities, Inc., BMO Capital Markets Corp., J.P. Morgan Securities LLC, KKR Capital Markets LLC, SMBC Nikko Securities America, Inc., and Truist Securities, Inc. are acting as joint book-running managers for this offering. FSK intends to use the net proceeds of this offering for general corporate purposes, including potentially repaying outstanding indebtedness under credit facilities and certain notes. This announcement does not constitute an offer to sell or a solicitation of an offer to buy any of the Notes, nor shall there be any offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. About FS KKR Capital Corp. FSK is a leading publicly traded business development company (BDC) focused on providing customized credit solutions to private middle market U.S. companies. FSK seeks to invest primarily in the senior secured debt and, to a lesser extent, the subordinated debt of private middle market companies. FSK is advised by FS/KKR Advisor, LLC. About FS/KKR Advisor, LLC FS/KKR Advisor, LLC (FS/KKR) is a partnership between FS Investments and KKR Credit that serves as the investment adviser to FSK and other business development companies. FS Investments is a global alternative asset manager dedicated to delivering superior performance and innovative investment and capital solutions. The firm manages over $83 billion in assets for a wide range of clients, including institutional investors, financial professionals and individual investors. FS Investments provides access to a broad suite of alternative asset classes and strategies through its best-in-class investment teams and partners. With its diversified platform and flexible capital solutions, the firm is a valued partner to general partners, asset owners and portfolio companies. FS Investments is grounded in its high-performance culture and guided by its commitment to building value for its clients, investing in its colleagues and giving back to its communities. The firm has more than 500 employees across offices in the U.S., Europe and Asia and is headquartered in Philadelphia . KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR's insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR's investments may include the activities of its sponsored funds and insurance subsidiaries. Forward-Looking Statements and Important Disclosure Notice This announcement may contain certain forward-looking statements, including statements with regard to future events or future performance or operations of FSK. Words such as "believes," "expects," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. Certain factors could cause actual results to differ materially from those projected in these forward-looking statements. Factors that could cause actual results to differ materially include changes in the economy, risks associated with possible disruption in FSK's operations or the economy generally due to terrorism, geo-political risks, natural disasters or pandemics such as COVID-19, future changes in laws or regulations and conditions in FSK's operating area and the price at which shares of FSK's common stock trade on the New York Stock Exchange. Some of these factors are enumerated in the filings FSK makes with the SEC. FSK undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information: Investor Relations Contact Anna Kleinhenn Anna.Kleinhenn@fsinvestments.com FS Investments Media Team Melanie Hemmert Melanie.Hemmert@fsinvestments.com View original content to download multimedia: https://www.prnewswire.com/news-releases/fsk-completes-public-offering-of-100-million-6-125-unsecured-notes-due-2030--302339667.html SOURCE FS Investments © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Carter’s foreign policy toward Cuba, Nicaragua and Haiti left huge marks on South Florida

Banco BBVA Argentina: Not The Best Play Among Argentine Banks

'It's Not an End to Itself': Daniel Horowitz Makes a Point About Populism